The following is a summary of "Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines," ...

Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 ...

In the 10-K report, under Item 7, "Management’s Discussion and Analysis of Financial Condition and Results of Operations," ...

Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).

Due to the ease of nanobody engineering, they can be employed in three nanobody-based therapeutic platforms: platform A, receptor antagonists to interfere with or block the activation of a certain ...

In this study, we critically evaluate the nanobody epitope prediction performance of two leading models: AlphaFold3 and AlphaFold2-Multimer (v.2.3.2), highlighting their strengths and limitations. Our ...

Among these, Nb15 showed clear accumulation in peripheral organs such as spleen and liver, as well as a clear tumor uptake in comparison to a control non-targeting nanobody. A bivalent construct of ...

Aflatoxin, a group of highly toxic second metabolites from some Aspergillus species such as Aspergillus flavus and Aspergillus paraticus, has still been threatening human health worldwide and the ...

Here, we have developed and used a novel, nanobody-based toolset, the GrabFP system, to interfere with the localization of GFP-tagged proteins along the apical-basal axis in the larval wing imaginal ...